SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

SANES

8.934

+0.01%↑

BBVA

17.96

+0.62%↑

MUV2

531.2

-0.11%↓

INGA

21.545

+0.3%↑

KBC

105.2

+1.06%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

186.9 0.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

183.95

Max

187.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

69.871

28.864

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

12.43

Darbuotojai

10,134

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+23.55% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.4B

18B

Ankstesnė atidarymo kaina

186.28

Ankstesnė uždarymo kaina

186.9

Naujienos nuotaikos

By Acuity

23%

77%

47 / 528 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-20 23:07; UTC

Rinkos pokalbiai

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

2025-11-20 22:22; UTC

Rinkos pokalbiai

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

2025-11-20 22:08; UTC

Rinkos pokalbiai

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

2025-11-20 21:57; UTC

Uždarbis

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-11-20 21:31; UTC

Uždarbis

Nvidia's Strong Results Show AI Fears Are Premature -- Update

2025-11-20 21:23; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

2025-11-20 21:07; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q Rev $156.9M >BULL

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q EPS 7c >BULL

2025-11-20 21:05; UTC

Uždarbis

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

2025-11-20 21:04; UTC

Uždarbis

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Rev $21B-$21.19B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Consumer Rev $894M

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Guidance

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Global Business Solutions Rev $3B

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

23.55% į viršų

12 mėnesių prognozė

Vidutinis 228.57 EUR  23.55%

Aukščiausias 246 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

5

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

47 / 528 reitingas Finansų sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat